HMI-115 is a human monoclonal antibody drug being developed by Chinese company Hope Medicine for the treatment of androgenetic alopecia (male and female pattern hair loss).
In November 2021, Hope Medicine received FDA approval to start Phase 2 clinical trials of HMI-115 for androgenetic alopecia. In 2020, the FDA also approved Phase 2 trials of the same drug for endometriosis. Phase 2 clinical trials of HMI-115 for hair loss are due to begin in the USA soon.
In Australia, Phase 1 trials are currently underway. The trial is due to last 6 months, with 20 participants receiving injections every 2 weeks (12 injections total).
Since November, one of the participants in this Phase 1 Australian trial – a 37 year old man with the Reddit username moeman32 – has been posting some details of his experience to Reddit.
Continue reading Hope Medicine Prolactin Receptor Monoclonal Antibody (HMI-115) for Hair Loss
